Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 2/20 | 0.41 |
| ▸ | ACP3 | P15309 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19614990 | 0.81 | PLAU (0.41) | SRCANPEPMEN1KMT2ALAP3 | |
| SCHEMBL14335168 | 0.79 | KDM4E (0.55) | MEN1KMT2A | |
| SCHEMBL14335289 | 0.79 | KMT2A (0.48) | SRCACP3MEN1CYP1A2KMT2A | |
| SCHEMBL14368141 | 0.78 | RIPK1 (0.49) | — | |
| SCHEMBL11400562 | 0.77 | ITGB3 (0.58) | ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL5400591 | 0.76 | RIPK1 (0.47) | — | |
| SCHEMBL7521194 | 0.76 | ITGB3 (0.38) | ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL5400597 | 0.76 | RIPK1 (0.47) | — | |
| SCHEMBL28039671 | 0.75 | CA9 (0.56) | SRCACP3MEN1CYP1A2KMT2A | |
| SCHEMBL27287608 | 0.74 | ITGB3 (0.46) | CYP1A2ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458072-B1 | BIS(ACETAMIDOPHENYL) GUANIDINOPHENYLETHYLPHOSPHONATES FOR USE IN THE PREVENTION AND/OR TREATMENT OF PAR-RELATED DISEASES | UNIV ANTWERPEN (BE) | 2020-09-30 | — | — | EP | disclosed |
| EP-3458072-A1 | BIS(ACETAMIDOPHENYL) GUANIDINOPHENYLETHYLPHOSPHONATES FOR USE IN THE PREVENTION AND/OR TREATMENT OF PAR-RELATED DISEASES | Universiteit Antwerpen (BE) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017198753-A1 | BIS(ACETAMIDOPHENYL) GUANIDINOPHENYLETHYLPHOSPHONATES FOR USE IN THE PREVENTION AND/OR TREATMENT OF PAR-RELATED DISEASES | UNIVERSITEIT ANTWERPEN (BE) | 2017-11-23 | — | — | WO | disclosed |
| US-20150349269-A1 | LUMINESCENT MATERIAL FOR ORGANIC OPTOELECTRIC DEVICE AND ORGANIC OPTOELECTRIC DEVICE AND DISPLAY DEVICE | CHEIL INDUSTRIES INC. (KR) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150349269-A1 | LUMINESCENT MATERIAL FOR ORGANIC OPTOELECTRIC DEVICE AND ORGANIC OPTOELECTRIC DEVICE AND DISPLAY DEVICE | OCIAD1, OR10J3, OCIAD2 | SRC 2567/4885ANPEP 3650/4885ACP3 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.